IBP

IBUPROFEN

Created: 2000-04-10
Last modified:  2020-06-05

Find related ligands:

Chemical Details

Formal Charge0
Atom Count33
Chiral Atom Count1
Bond Count33
Aromatic Bond Count6
2D diagram of IBP

Chemical Component Summary

NameIBUPROFEN
Synonyms2-(4-ISOBUTYLPHENYL)PROPIONIC ACID
Systematic Name (OpenEye OEToolkits)(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
FormulaC13 H18 O2
Molecular Weight206.281
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs10.04O=C(O)C(c1ccc(cc1)CC(C)C)C
SMILESCACTVS3.341CC(C)Cc1ccc(cc1)[CH](C)C(O)=O
SMILESOpenEye OEToolkits1.5.0CC(C)Cc1ccc(cc1)C(C)C(=O)O
Canonical SMILESCACTVS3.341 CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O
Canonical SMILESOpenEye OEToolkits1.5.0 CC(C)Cc1ccc(cc1)[C@H](C)C(=O)O
InChIInChI1.03 InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
InChIKeyInChI1.03 HEFNNWSXXWATRW-JTQLQIEISA-N

Drug Info: DrugBank

DrugBank IDDB09213 
NameDexibuprofen
Groups
  • approved
  • investigational
DescriptionDexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259]. For Metabolism, Enzymes, Carriers, Transporters Sections, refer to [Ibuprofen].
Synonyms
  • d-ibuproten
  • Dexibuprofeno
  • (S)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
  • Dexibuprofen
  • (+)-(S)-p-isobutylhydratropic acid
IndicationFor more information, refer to [ibuprofen].
Categories
  • Acids, Carbocyclic
  • Agents causing hyperkalemia
  • Agents that produce hypertension
  • Anti-Inflammatory Agents
  • Anti-Inflammatory Agents, Non-Steroidal
ATC-CodeM01AE14
CAS number51146-56-6

Drug Targets

NameTarget SequencePharmacological ActionActions
Prostaglandin G/H synthase 2MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFY...unknowninhibitor
Prostaglandin G/H synthase 1MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFG...unknowninhibitor
Apoptosis regulator Bcl-2MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFS...unknownnegative modulator
ThrombomodulinMLGVLVLGALALAGLGFPAPAEPQPGGSQCVEHDCFALYPGPATFLNASQ...unknownmodulator
Tissue-type plasminogen activatorMDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIY...unknownmodulator
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL175
PubChem 39912
ChEMBL CHEMBL175
ChEBI CHEBI:43415
CCDC/CSD JEKNOC12, JEKNOC11, IBPRAC, SOGLAC, IBPRAC01, JEKNOC10, IBPRAC04, SODDIZ, JEKNOC, OWIGEH, ROQMAN, HUPPAJ, IBPRAC21, EQAKUF, EQAKOZ, QAKTAB
COD 1559416, 4511599, 2006278, 4503558, 4503559, 2104678, 2300212, 2300213, 2300214, 2300216, 2300215, 2300217, 2300218, 2300219, 2300221, 2300224, 2209438